Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Revolutionizing mRNA Cancer Vaccines with Nanosized Bacterial Outer Membrane Vesicles

Objetivo

mRNA vaccines have garnered significant attention for their transformative potential in cancer immunotherapy. Despite their promise in eliciting immune responses against tumor antigens, mRNA vaccines still face several challenges, primarily related to limitations of lipid nanoparticle (LNP)-based formulations and the immunosuppressive role of the tumor microenvironment. Another immunotherapy modality, immune checkpoint inhibitors (ICIs), which block inhibitory signals that suppress T cell activation, can enhance the effectiveness of mRNA vaccines. However, ICIs have their own limitations, including low response rates and significant immune-related adverse events. BactoNanoVax aims to revolutionize cancer immunotherapy by combining these two cutting-edge immunotherapy modalities co-delivered through outer membrane vesicles (OMVs) derived from engineered bacteria. I hypothesize that by leveraging the unique capabilities of OMVs over LNPs as drug delivery systems (i.e. superior stability, immunogenicity, cost of production), I will enhance the efficacy of mRNA vaccines and ICIs, drastically overcoming the immunosuppressive tumor microenvironment and leading to enhanced therapeutic outcomes in immunotherapy-resistant tumors. BactoNanoVax will also integrate a tumor microenvironment reprogramming strategy, repurposing the clinically approved anti-histamine ketotifen to optimize OMVs intratumoral delivery and immune cell infiltration. This highly interdisciplinary research combines expertise in tumor biology, synthetic biology, microbiology, immunology and drug delivery, and it represents a pioneering approach in cancer immunotherapy. The development of OMV-based immunotherapy will revolutionize the field of precision oncology by providing a novel, highly effective therapeutic product that reduces the risk of adverse events, eliminates the need for additional immune adjuvants, and is cost-effective in production and transportation.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC - HORIZON ERC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-STG

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

UNIVERSITY OF CYPRUS
Aportación neta de la UEn
€ 1 500 000,00
Dirección
AVENUE PANEPISTIMIOU 2109 AGLANTZI
1678 Nicosia
Chipre
Región
Κύπρος Κύπρος Κύπρος
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 500 000,00

Beneficiarios (1)